Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
endocrine save search
Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim
Published: 2023-08-03 (Crawled : 21:00) - prnewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 4.35%
C: 1.85%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
RCUS 4 | $14.59 -1.69% 0.0% 600K
|
Health Technology
|
| O: 0.11%
H: 1.42%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.43%
H: 0.0%
C: 0.0%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: -0.23%
H: 1.85%
C: 0.15%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.8%
H: 0.99%
C: -1.29%
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 0.45%
H: 4.02%
C: 0.45%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.01%
H: 1.23%
C: -0.15%
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: 0.69%
H: 3.08%
C: 0.0%
companies expected pancreatic tumor endocrine growth market
Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
Published: 2023-06-26 (Crawled : 12:20) - globenewswire.com
PBLA | $0.4895 -6.31% 66K
|
Professional, Scientific, and T...
|
| O: 0.89%
H: 0.73%
C: -9.29%
presentation endocrine diabetes
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.07%
H: 11.92%
C: 11.25%
pharma conference six achondroplasia endocrine trial results
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
Published: 2023-06-08 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.36%
H: 0.18%
C: -1.99%
pharma conference six achondroplasia presentation endocrine results study
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
Published: 2023-06-05 (Crawled : 15:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.0%
H: 0.15%
C: -0.26%
tepezza endocrine meeting trial therapeutics
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
Published: 2023-05-13 (Crawled : 00:20) - globenewswire.com
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
| Email alert
Add to watchlist
rare pharma endocrine
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
Published: 2023-05-08 (Crawled : 12:00) - globenewswire.com
LUMO | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -0.08%
H: 1.63%
C: 0.08%
pharma trials endocrine meeting
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
Published: 2023-05-02 (Crawled : 17:00) - prnewswire.com
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -0.81%
H: 0.19%
C: -6.94%
arv-471 quantum leap endocrine trial study platform
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
Published: 2023-04-27 (Crawled : 15:20) - biospace.com/
LUMO | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: 4.61%
H: 1.82%
C: -7.29%
pharma trials endocrine meeting
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
Published: 2023-04-06 (Crawled : 14:00) - biospace.com/
PBLA | $0.4895 -6.31% 66K
|
Professional, Scientific, and T...
|
| O: 2.29%
H: 16.42%
C: 6.0%
presentation endocrine meeting
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2023-03-28 (Crawled : 11:00) - prnewswire.com
VKTX | $63.38 -2.0% -2.04% 3M
|
Health Technology
|
| O: 34.98%
H: 25.83%
C: 25.43%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: -0.07%
H: 5.37%
C: 4.8%
vk2735 agonist trial therapeutics results endocrine disorders obesity phase 1
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
Published: 2023-01-26 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
endocrine therapeutics endocrine disorders
Endocrinology drugs market size to grow by USD 36551.24 Million: Increase in the incidence of endocrine disorders remains key growth driver - Technavio
Published: 2022-12-07 (Crawled : 00:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: 0.0%
H: 11.11%
C: 2.78%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.17%
H: 1.09%
C: 1.01%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.41%
H: 1.75%
C: 0.66%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.14%
H: 2.32%
C: 2.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
ORMP A | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: 0.48%
H: 4.55%
C: 3.47%
endocrine growth market endocrine disorders
Global Endocrine Testing Market to Reach $15.3 Billion by 2027
Published: 2022-09-20 (Crawled : 20:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
DGX | $128.44 2.01% 0.0% 1.6M
|
Health Services
|
| O: 0.51%
H: 0.93%
C: -2.56%
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.45%
H: 0.55%
C: -3.53%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.55%
H: 1.02%
C: -2.16%
global endocrine market
At 8% CAGR, Global Endocrine Peptide Test Market Size & Share to Surpass US$ 11 Billion By 2028 | Endocrine Peptide Test | Industry Trends, Share, Growth, Value, Analysis & Forecast Report By Zion Market Research
Published: 2022-07-06 (Crawled : 17:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.07%
H: 0.62%
C: -0.13%
research report test endocrine market
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
Published: 2022-06-13 (Crawled : 17:00) - prnewswire.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -2.61%
H: 0.71%
C: -1.65%
endocrine children injection achondroplasia
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
Published: 2022-06-09 (Crawled : 13:20) - globenewswire.com
CRXT | $0.0475
|
|
| O: -3.89%
H: 7.43%
C: -2.17%
jatenzo endocrine therapeutics
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
Published: 2022-06-09 (Crawled : 13:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -7.3%
H: 0.0%
C: 0.0%
pharma conference endocrine phase 3 phase 2b
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
Published: 2022-06-02 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -3.15%
H: 4.36%
C: 3.97%
conference disease education endocrine eye therapeutics
Global Endocrine Testing Products Market to Surpass US$ 23,160.1 Million by 2030 - Coherent Market Insights
Published: 2022-05-25 (Crawled : 18:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.95%
H: 0.0%
C: 0.0%
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: 0.16%
H: 0.34%
C: -0.87%
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
|
| O: -0.8%
H: 1.09%
C: 0.36%
BIO | $279.73 -0.46% 0.0% 290K
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.93%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -1.33%
H: 1.54%
C: -0.01%
endocrine market test
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
COMP | $3.24 -0.61% 6.48% 2.4M
|
Your saved searches
Save your searches and get alerts when important news are released.